New hope for hard-to-treat lung cancer: combo therapy enters phase 2 trial

NCT ID NCT07306624

Recruiting now Disease control Sponsor: STCube, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 03, 2026 · Last updated May 14, 2026 · Updated 23 times

Summary

This study tests a new drug called nelmastobart combined with the chemotherapy docetaxel in people with advanced non-small cell lung cancer whose cancer has stopped responding to or cannot tolerate standard platinum-based chemo or immunotherapy. About 62 participants will receive the combination to see if it slows cancer growth and is safe. The goal is to find a better option for those with limited choices.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Kangbuk Samsung Hospital
RECRUITING

Seoul, South Korea

Contact
Korea University Anam Hospital
NOT_YET_RECRUITING

Seoul, South Korea

Contact
Samsung Medical Center
RECRUITING

Seoul, South Korea

Contact
Seoul National University Bundang Hospital
NOT_YET_RECRUITING

Seoul, South Korea

Contact
The Catholic University of Korea St. Vincent's Hospital
NOT_YET_RECRUITING

Gyeonggi-do, South Korea

Contact

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER